ArticleStem cell reviews and reports2025
Stem Cells Run Like Clockwork for Stroke Therapeutics.
Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research on stem cell therapy for brain injury: A bibliometric and visual analysis (2009-2025).IBRO neuroscience reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence reveals an association between stroke and circadian rhythm, but whether circadian rhythm manifests in stem cells remains underexplored. Here, we examined the presence of circadian rhythm in stem cells in both ambient and stroke conditions. Under ambient culture conditions, umbilical cord-derived mesenchymal stem cells (UC-MSCs) exhibited a cycle of 10–15 h with a slight frameshift between cell mobilization and proliferation. BMAL1 and PER2 clock gene expressions matched cell mobilization rhythms. The proliferative marker c-Fos expression directly mirrored cell proliferation, but inversely reflected cell mobilization and clock genes, whereas the cytoskeletal marker F-actin expression displayed an oscillation pattern independent of stem cell activity rhythms and clock genes. Under oxygen-glucose deprivation (OGD) conditions, UC-MSCs with high levels of BMAL1/PER2 (HBP) significantly improved survival and viability of OGD-exposed human neural progenitor cells (hNPCs) compared to moderate levels (MBP) and low levels (LBP) of BMAL1/PER2, with clock gene expressions mirroring the therapeutic effects of HBP UC-MSCs. During this acute time-point post-OGD when HBP UC-MSCs rescued hNPCs from OGD, F-actin expression robustly increased while c-Fos expression moderately upregulated, implicating a more active cytoskeletal remodeling than cell proliferation towards cell repair. These results suggest that optimizing the timing of stem cell activity (i.e., high levels of BMAL1/PER2) enhances stem cell therapy for stroke.
Indexed as
Identifiers
40676475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.